Literature DB >> 4005846

Evidence for a novel pituitary factor that potentiates the mitogenic effect of estrogen in human breast cancer cells.

T C Dembinski, C K Leung, R P Shiu.   

Abstract

Estrogen, prolactin, and other tissue-derived factors are implicated in the etiology and pathophysiology of human breast cancer (HBC). In a previous study, we demonstrated that a factor(s) secreted by rat pituitary tumor cells (GH3) synergizes with estrogen to induce growth of HBC cells (T-47D) transplanted into athymic nude mice. The present studies were carried out to characterize further this pituitary growth factor. Pituitary tumor cell lines (GH3, GH1, 235-1, and AtT-20) and normal rat pituitaries were transplanted s.c. into estrogen-treated (estradiol valerate injection, 500 micrograms/14 days) athymic nude mice which also received T-47D cells. The influence of the presence of these normal and tumorous pituitary cells on growth (size and weight) of T-47D tumors was monitored for 49 to 56 days. The results indicate that factor(s) from normal rat pituitary glands as well as from the GH1 and GH3 but not 235-1 and AtT-20 pituitary tumor cells were able to potentiate the growth of T-47D tumors in estrogenized mice. To ascertain whether or not prolactin and/or growth hormone are responsible for the growth-promoting activity, purified human and ovine growth hormone and ovine prolactin were administered to estrogenized athymic nude mice either by daily s.c. injection (100 micrograms/day) or by constant infusion using Alzat osmotic minipumps (1.25 and 5.0 micrograms/h) for 29 to 56 days. None of these treatments stimulated the growth of the T-47D tumors, suggesting that prolactin, growth hormone, and their intermediates may not be directly involved. We further determined whether the factor from pituitary tumor cells was present in serum-free conditioned medium and could stimulate the growth of HBC cells in vitro. Conditioned medium from GH3 and GH1 but not from 235-1 and AtT-20 pituitary cells significantly stimulated growth of T-47D cells in the presence of estradiol (10(-10) M) after 12 days of culture in a serum-free medium (Dulbecco's modified Eagle's medium containing bovine serum albumin, 0.5 mg/ml). Optimal serum-free growth of T-47D cells (2-fold above control) was observed in the presence of estradiol (10(-10) M) and conditioned medium (30% v/v) from 48-h cultures of GH3 cells. The bovine serum albumin concentration of the serum-free medium (Dulbecco's modified Eagle's medium) was also important: optimal T-47D cell proliferation was observed with BSA between 0.5 and 2.0 mg/ml. Conditioned medium preparations from serum-pretreated flasks (without cells) from GH3 cell monolayers for zero time and from actinomycin D plus cycloheximide-inhibited GH3 cells were inactive.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling.

Authors:  K S Russell; M P Haynes; D Sinha; E Clerisme; J R Bender
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells.

Authors:  Maria Marino; Filippo Acconcia; Francesco Bresciani; Alessandro Weisz; Anna Trentalance
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

3.  The effects of estrogen on human breast carcinomas serially transplanted into nude mice.

Authors:  T Fukutomi; K Yamaguchi; T Kubota; T Ikeda; K Enomoto; K Ishibiki; O Abe
Journal:  Jpn J Surg       Date:  1989-11

4.  Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability.

Authors:  Matthew J Sikora; Michael D Johnson; Adrian V Lee; Steffi Oesterreich
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

5.  Evidence for a nonprolactin, non-growth-hormone mammary mitogen in the human pituitary gland.

Authors:  C B Newman; H Cosby; H G Friesen; M Feldman; P Cooper; V De Crescito; M Pilon; D L Kleinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Optimization of estrogen growth response in MCF-7 cells.

Authors:  T E Wiese; L G Kral; K E Dennis; W B Butler; S C Brooks
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

7.  Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells.

Authors:  R Mira-y-Lopez; J Joseph-Silverstein; D B Rifkin; L Ossowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 8.  Mitogenic regulation of normal and malignant breast epithelium.

Authors:  M E Lippman; R B Dickson
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct

9.  Undetected αKlotho in serum is associated with the most aggressive phenotype of breast cancer.

Authors:  Bruna Cristina Borges; Pedro Augusto Do Amaral; Luiz Ricardo Soldi; Victor Luigi Costa Silva; Fernanda Carvalho De Souza; Felipe Andrés Cordeiro Da Luz; Rogério Agenor De Araújo; Marcelo José Barbosa Silva
Journal:  Mol Clin Oncol       Date:  2022-02-25

Review 10.  The oxytocin receptor signalling system and breast cancer: a critical review.

Authors:  Huiping Liu; Christian W Gruber; Paul F Alewood; Andreas Möller; Markus Muttenthaler
Journal:  Oncogene       Date:  2020-08-11       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.